Description_x000D_ Biochem/physiol Actions_x000D_ PF-06297470 is a potent negative allosteric modulator of the Metabotropic Glutamate Receptor 5 (mGluR5). PF-06297470 binds to mGluR5 with a Ki of 0.9 nM. The compound PF-06297470 displays slight antagonism of mGluR1 (IC50 = 30.5 mM), with no agonist or antagonist activities against any other mGlu receptor subtype at concentrations up to 50 mM. PF-06297470 reduces dyskinesia in a rodent (MPTP)-rendered Parkinsonian model of L-DOPA-induced dyskinesia (PD-LID)._x000D_ Features and Benefits_x000D_ This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm._x000D_ Other Notes_x000D_ This compound was developed by Pfizer for Neuroscience research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer._x000D_ To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Pfizer Inc._x000D_ Pfizer is a registered trademark of Pfizer, Inc.